In a landmark divergence from federal medical oversight, a newly finalized state regulatory framework has opened the door for biotechnology companies to market unapproved experimental therapeutics directly to consumers. Under operational guidelines that took effect in late July, treatments that have completed preliminary human safety testing—sometimes involving as few as ten healthy volunteers—can now seek administrative authorization to be prescribed and administered at specialized regional clinics. By establishing an independent oversight mechanism outside the purview of the U.S. Food and Drug Administration (FDA), this state initiative creates a novel legal and commercial paradigm, allowing drug developers to set their own retail prices and sell experimental biological interventions to patients willing to pay out-of-pocket.
The implementation of these rules marks a fundamental shift in the nationwide debate over medical autonomy, clinical safety, and the boundaries of federal drug regulation. While traditional access programs across the United States strictly restrict unapproved drugs to terminally ill individuals who have exhausted all conventional options, this newly enacted model theoretically extends access to any patient who provides informed consent and possesses the financial resources to pay. The scope of eligible interventions ranges from therapies targeting severe neurodegenerative conditions and rare diseases to unproven preventive therapeutics advocated by the growing longevity and healthspan movement.
From Terminal Rights to Universal Commercial Access
To understand the magnitude of this shift, one must examine the evolution of "Right to Try" legislation in the United States over the past decade. The movement gained initial national momentum with the passage of the federal Right to Try Act in 2018. Designed to give terminally ill patients access to investigational treatments without explicit FDA approval, the federal law required that drugs complete at least a Phase 1 clinical trial and remain under active development within the FDA regulatory pipeline. However, federal provisions strictly prohibited drug developers from profiting off these treatments, capping charges to the direct costs of manufacturing and administration.
The newly operational state framework fundamentally dismantles these boundaries in two key ways: scope and economics. By removing the requirement for a terminal diagnosis, the law expands eligibility to individuals seeking treatments for non-fatal chronic conditions, early-stage pathologies, and wellness or anti-aging interventions. Furthermore, it replaces cost-recovery price caps with a free-market pricing model, enabling biotech ventures to treat early-stage access not merely as a compassionate concession, but as a viable commercial revenue strategy.
Under the state’s codified administrative rules, biotech companies seeking market access must pay a $12,500 application fee to an independent Experimental Treatment Review Board (ETRB). If approved by the board, the company is authorized to distribute its therapeutic compound through state-licensed clinics. The state health department requires that each application undergo evaluation by a panel composed of a locally licensed physician, scientific experts, and an ethicist, with the intent of maintaining clinical accountability while bypassing the years-long federal approval process.
The Unconventional Coalition Shaping the Deregulatory Model
Unlike early Right to Try legislation, which was primarily championed by libertarian policy institutes and terminally ill patient advocacy groups, the driving force behind this expanded framework stems from an unusual alliance between state lawmakers, longevity advocates, and tech-sector venture capitalists.
The legislative foundation began taking shape when state lawmakers sought to expand medical access toward preventive medicine rather than reactive disease treatment. During the drafting phase, national advocacy organizations such as the Alliance for Longevity Initiatives (A4LI)—a nonprofit focused on advancing policies to extend healthy human lifespan—intervened to provide policy language and expert testimony.
The momentum accelerated through the involvement of technology entrepreneurs and longevity investors associated with alternative governance models. Among these figures is Niklas Anzinger, an investor previously involved in establishing regulatory free zones in international jurisdictions such as Próspera—a private city and special economic zone in Honduras known for hosting experimental gene and stem-cell therapy clinics. Recognizing the potential of leveraging U.S. state sovereignty, advocates pivoted toward adapting these light-touch regulatory concepts to domestic law, arguing that state-level precedents offer greater stability and institutional legitimacy than offshore experimental hubs.
Working alongside biotech developers and state legislative leaders, proponents crafted operational guidelines governing how experimental clinics must operate, leading to formal legislative passage in mid-2025 and the recent publication of administrative rules by state health authorities.
Governance Mechanics: The Experimental Treatment Review Board
To comply with state mandates, private entities under the broader organizational umbrella of longevity venture firms have established the state’s first operational review board: the Montana Experimental Treatment Review Board (ETRB). Operated as a private entity under a local corporate structure, the board serves as the gatekeeper for companies seeking to commercialize unapproved therapeutics within state borders.
While financed by the $12,500 filing fees collected from corporate applicants, board organizers emphasize that review panel members operate independently and receive flat-rate compensation regardless of whether an application is approved or rejected. The inaugural five-member panel reflects a deliberate blend of clinical medicine, bioethics, and specialized research in geroscience:
- Clinical Expertise: A state-licensed oncologist tasked with evaluating medical safety and patient monitoring protocols.
- Bioethical Oversight: A prominent academic bioethicist known for scholarly work advocating for patient pharmaceutical autonomy and self-medication rights.
- Scientific Assessment: Recognized researchers in the biology of aging, including former senior officials from the National Institutes of Health (NIH) Division of Aging Biology, executive leadership from international geroscience foundations, and academic directors overseeing major healthspan incentive competitions.
Supporters of the review board model contend that this concentration of domain expertise ensures rigorous scientific evaluation while stripping away the bureaucratic delays characteristic of federal agencies. Critics, however, question whether private review boards funded by applicant fees can maintain absolute neutrality, particularly when operating within an ecosystem designed to accelerate market entry.
Early Adopters and Corporate Hesitancy
Despite the strong influence of the longevity community in passing the law, the initial wave of corporate applications focuses primarily on conventional disease targets rather than radical life extension.
Two initial applications have already been submitted to the review board for formal evaluation. One high-profile applicant is WinSanTor, a biotechnology firm developing a therapeutic candidate for peripheral neuropathy—a debilitating nerve condition frequently caused by diabetes or chemotherapy treatment. Although the compound is currently undergoing standard Phase 2 clinical trials, company leadership reports receiving overwhelming demand from patients seeking immediate access outside of trial enrollment constraints. By entering the state program, the firm aims to provide early access to paying patients while simultaneously collecting real-world observational data that could potentially bolster its broader development program.
However, the legal ambiguity surrounding state-level authorization has created a sharp divide within the biotech industry. Many early-stage companies remain deeply hesitant to participate. Executives from international biotech startups, including developers working on rare neurological therapies, have expressed concerns that selling unapproved drugs under state law could provoke regulatory retaliation from the FDA. Because the FDA holds ultimate authority over nationwide drug approvals, commercialization rights, and interstate commerce, companies fear that participating in a non-federal access scheme could compromise their standing during federal clinical trial reviews or future New Drug Applications (NDAs).
Federal Friction and Legal Ambiguities
The tension between state dereulatory ambitions and federal supremacy presents an unprecedented legal conundrum. When pressed for guidance on how participation in state-sanctioned experimental programs might affect a company’s federal standing, federal regulators have maintained a strict policy of silence, reiterating only the statutory parameters of the federal Right to Try Act.
Legal scholars and health policy experts emphasize that this lack of federal clarity carries significant risk for biotech developers and clinical operators:
- Jurisdictional Risk: Under the Supremacy Clause of the U.S. Constitution, federal drug safety laws enforced by the FDA legally supersede state legislation. Should federal authorities determine that the distribution of an experimental compound constitutes illegal interstate drug marketing or unapproved human experimentation, state legislation may offer limited protection against federal injunctions or enforcement actions.
- Regulatory Volatility: Policy interpretations within federal agencies can shift dramatically between presidential administrations. A relaxed enforcement stance today could quickly transition into aggressive regulatory intervention tomorrow, leaving participating companies vulnerable to legal liability.
- The Expanded Access Alternative: Federal regulatory experts note that the FDA already operates an "Expanded Access" (or compassionate use) program designed to grant severely ill patients access to investigational drugs. Historically, the FDA approves over 99% of these requests within expedited timeframes. The key distinction lies in oversight and pricing: federal Expanded Access requires FDA oversight to protect patient safety and restricts companies from profiting off vulnerable individuals, whereas the state model waives federal oversight and permits uncapped commercial pricing.
Clinical Risks and Ethical Implications
Beyond the legal debate lies a profound clinical reality: early-stage human safety testing is inherently limited. Phase 1 trials are designed primarily to determine basic metabolic tolerance and identify immediate toxicity in small, tightly controlled cohorts. They are not engineered to establish therapeutic efficacy or detect low-frequency, severe adverse events.
Biomedical statistics reveal that approximately 17% of candidate drugs fail in Phase 3 clinical trials due to unpredicted safety hazards—after having successfully cleared both Phase 1 and Phase 2 evaluations. Consequently, administering Phase 1-cleared compounds to a broader patient population outside of rigorous clinical trial protocols exposes consumer-patients to substantial safety risks, including unmitigated organ toxicity, unforeseen drug interactions, or accelerated disease progression.
From an economic perspective, allowing unrestricted commercial pricing introduces complex ethical questions surrounding equity and medical monetization. While some participating companies express intentions to offer experimental compounds at cost, others acknowledge that market pricing for rare disease therapies and novel biologicals often stretches into hundreds of thousands of dollars. Without insurance coverage—which will not cover unapproved therapies—access to state-approved experimental treatments will remain largely restricted to high-net-worth individuals, effectively transforming early-stage clinical access into a cash-pay boutique industry.
Industry Implications and the Road Ahead
As specialized clinical facilities across the state outfit treatment suites, hire medical directors, and prepare to administer the first state-sanctioned experimental therapies, the global biotechnology and financial sectors are watching closely.
If this state-level model proves commercially viable and clinically stable, it could serve as a legislative blueprint for other states seeking to attract biotech investment, medical tourism, and venture capital. Such a trend would fundamentally decentralize the American pharmaceutical market, establishing regional ecosystems where experimental medicine operates alongside conventional healthcare systems.
Conversely, if high-profile adverse events occur, or if federal enforcement agencies intervene to assert statutory dominance, the movement could face severe legal setbacks, casting a shadow over state-level deregulatory experiments. For now, the implementation of these rules marks the beginning of an unprecedented live experiment in health policy—testing whether free-market access, private review boards, and patient autonomy can safely coexist outside the traditional boundaries of federal drug regulation.
